(+)-corybulbine | 518-77-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: (+)-corybulbine
• 英文别名: corybulbine；2,9,10-trimethoxy-13-methyl-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinolin-3-ol；dl-Corybulbine；Corybulbin；2,9,10-trimethoxy-13-methyl-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinolin-3-ol
• CAS: 518-77-4；16562-09-7；27313-87-7；101541-43-9
• 化学式: C₂₁H₂₅NO₄
• 分子量: 355.434
• InChiKey: OBVLTWCOTSTMNM-UHFFFAOYSA-N

物化性质

• 熔点：
  242°
• 比旋光度：
  D20 +303° (c = 1.4 in CHCl3)
• 沸点：
  488.45°C (rough estimate)
• 密度：
  1.1914 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PHARMACEUTICAL PRODUCT FOR TREATING ANKYLOSING SPONDYLITIS AND COMBINED IMMUNE DEFECT, AND PREPARATION AND APPLICATION THEREOF
  申请人：Beijing Lu De Kai Qi Co., Ltd.

  公开号：EP3441077A1

  公开（公告）日：2019-02-13

  A pharmaceutical product for treating ankylosing spondylitis for combined immunodeficiency which is prepared from a Rosa roxbunghii extract, an Artemisia argyi extract, a hippocampus extract, and a Corydalis Rhizoma extract in a weight ratio of (1-10):(0.5-2):1:(1-10) by supercritical fluid extraction. The pharmaceutical product facilitates in vivo dissolution and human body absorption.

  一种治疗联合免疫缺陷强直性脊柱炎的药物产品，由蔷薇提取物、青蒿提取物、海马提取物和堇菜提取物按重量比（1-10）:(0.5-2):1:(1-10)通过超临界流体萃取制备而成。该药品有利于体内溶解和人体吸收。
• METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS
  申请人：Mallinckrodt LLC

  公开号：EP2654727A1

  公开（公告）日：2013-10-30
• COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND ITS PRODUCTION PROCESS
  申请人：Eleonor SPRL

  公开号：EP3672575A1

  公开（公告）日：2020-07-01
• Compounds exhibiting efflux inhibitor activity and composition and uses thereof
  申请人：Wempe Fitzpatrick Michael

  公开号：US20070254859A1

  公开（公告）日：2007-11-01

  At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
• Sustained-Release Opiate and Opiate Derivative Compositions
  申请人：Schaefer Carl J.

  公开号：US20110077222A1

  公开（公告）日：2011-03-31

  The present invention provides sustained-release opiate compositions. In particular, the present invention provides sustained-release opiate compositions that include an opiate attached to a blood albumin binder. The present invention also relates to methods of administering an opiate with a sustained release pharmacokinetic profile.